Short answer
Hims & Hers Health, Inc. (HIMS) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $890M (up 48.6% year over year) with net income of −$33M.
Q3 2026 key financials · XBRL
- Revenue
- $890M
- +48.6% YoY · +18.2% QoQ
- Net income
- −$33M
- −309.5% YoY · +61.7% QoQ
- Operating margin
- -7.4%
- Gross margin
- 57.2%
- EPS (diluted)
- −$0.13
- −316.7% YoY · +65.8% QoQ
Source: XBRL data from the Hims & Hers Health, Inc. (HIMS) Q3 2026 10-Q on SEC EDGAR. USD.
Hims & Hers Health, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $890.4M, up 49% YoY from $599.0M, driven by Rest of World revenue $233.3M, up 321%
- Gross margin 57% vs 74% YoY; net loss $33.0M vs net income $15.8M
- Hers strongest growth driver, 45% of U.S. revenue, versus approximately 40% YoY
- Operating cash flow $65.4M vs $148.7M YoY; free cash flow $26.0M vs $79.4M
- Near-term headwinds: gross margin below comparative periods from weight loss offerings, international acquisitions, and shorter shipping cadences
Risk Factors
- New regulatory risk: testosterone therapy launched in 2026, with Schedule III products subject to DEA registration and controlled-substance requirements
- Most material update: FDA directly named Hims & Hers in February 2026 GLP-1 statement, while HHS referred the company to DOJ
- Legal exposure: FTC and state plaintiffs filed a July 2026 ROSCA and FTC Act complaint, with approximately $60 million accrued
- Operational risk: branded GLP-1 transition may reduce demand and increase churn among customers using compounded alternatives
- Financial risk: branded GLP-1 procurement costs may pressure margins, with limited ability to pass through price increases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Hims & Hers Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.